Joint stroke management includes the use of anticoagulants, anti-inflammatory, and thrombolytics; however, with more knowledge of the SARS-CoV-2 affinity for ACE-2 receptors within endothelial lumens, the use of angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme (ACE) inhibitors was started as a trial to help stabilize patients' symptoms [36]. Here, ACE is linked to stroke disorder.